Wegovy Monitoring Schedule: Every Lab and Exam a Woman Needs, and When

How Wegovy Works: The Physiology That Shapes What You Monitor

Semaglutide 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist injected once weekly. It mimics the gut hormone GLP-1, which your body releases after eating. By binding GLP-1 receptors in the hypothalamus, brainstem, and gut, semaglutide slows gastric emptying, reduces appetite, and lowers calorie intake over time.

In the STEP-1 trial, 1,961 adults without diabetes who received semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group. About 86% of the STEP-1 population was female, which makes this trial unusually informative for women relative to most obesity-medicine data.

Why Women's Physiology Changes the Monitoring Picture

Women have higher baseline percent body fat, a cyclic hormonal environment, and distinct fat-distribution patterns driven by estrogen. GLP-1 receptors are expressed in ovarian tissue, and semaglutide's effects on gastric emptying interact with progesterone-driven gut motility changes across the menstrual cycle. These factors do not change the dosing schedule, but they change which labs matter and how to interpret them.

The GLP-1 Mechanism and Thyroid C-Cells

Semaglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent data. GLP-1 receptors are expressed on rodent thyroid C-cells; whether the same applies to humans at clinical doses remains uncertain. This uncertainty is the reason thyroid monitoring is not optional.

Baseline Labs and Exams: What to Order Before Dose 1

Get your baseline panel done within four weeks before your first injection. A narrow baseline window matters because semaglutide begins changing metabolic parameters quickly, sometimes within the first two to four weeks.

Metabolic Panel

Order a comprehensive metabolic panel (CMP) to capture:

• Fasting glucose and HbA1c (semaglutide lowers both; you need a pre-treatment value)
• Creatinine and eGFR (volume losses from nausea can stress kidneys acutely)
• ALT and AST (fatty liver is common in women with PCOS and metabolic syndrome; a baseline protects you medically and legally if transaminases rise later)
• Bilirubin (gallstone risk increases with rapid weight loss)

The FDA prescribing information for Wegovy does not mandate a specific metabolic lab schedule, but obesity-medicine clinical practice guidelines from the American Association of Clinical Endocrinology recommend fasting glucose and lipids at baseline for all patients starting GLP-1 therapy.

Lipid Panel

A fasting lipid panel at baseline is standard. In the STEP-1 trial, semaglutide 2.4 mg reduced LDL-C by approximately 3.7% and triglycerides by 25.6% at 68 weeks. Women with PCOS often present with elevated triglycerides and low HDL; knowing your starting point lets you separate the drug effect from underlying dyslipidemia.

Thyroid Panel

Order TSH at minimum. If you have a personal history of thyroid nodules, Hashimoto thyroiditis, or a first-degree relative with medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), Wegovy is contraindicated and should not be started. A neck exam for palpable nodules is appropriate at the same visit.

PCOS-Specific Baseline Panel

Women with PCOS represent a large share of Wegovy candidates and deserve a condition-specific baseline:

• Fasting insulin and HOMA-IR (to document insulin resistance before treatment)
• Free and total testosterone, DHEAS, SHBG (androgenic PCOS phenotype tracking)
• LH and FSH ratio if menstrual irregularity is present
• Prolactin to rule out secondary causes of anovulation

Weight loss in PCOS often restores menstrual regularity within three to six months, which has fertility implications you need to anticipate (see the Pregnancy section below).

Blood Pressure, Heart Rate, and Weight

Record weight (with body composition if available), blood pressure, and resting heart rate. Semaglutide raises heart rate by a mean of approximately 1 to 4 beats per minute in some patients. Women in perimenopause or postmenopause already experience resting heart rate variability; an accurate baseline prevents misattribution.

The Dose-Escalation Phase: Monitoring During Weeks 1 to 20

Wegovy uses a five-step dose escalation: 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. Each step lasts four weeks. Side effects are most pronounced during escalation.

Gastrointestinal Symptom Tracking

Nausea, vomiting, diarrhea, and constipation affect 44% of semaglutide-treated participants in STEP-1 versus 16% on placebo. Women tend to have slower baseline gastric emptying than men, and progesterone further slows motility in the luteal phase of the cycle. This means GI side effects may feel worse in the week before your period. Keeping a symptom diary tied to cycle day helps distinguish drug effect from hormonal variation.

No lab is required specifically for GI symptoms unless vomiting is frequent enough to raise concern about dehydration or electrolyte imbalance. If you are vomiting more than three times daily for more than two days, a basic metabolic panel (BMP) to check sodium, potassium, and creatinine is appropriate.

Injection Site Assessment

At each clinical touchpoint during escalation (typically weeks four, eight, and twelve), inspect injection sites. Rotate among abdomen, thigh, and upper arm. Women with lipodystrophy or prior insulin injection sites should avoid those areas. No lab is needed here, but photographs of unusual nodules are medically useful.

Weight Response Check at Week 16

A clinically meaningful weight loss of at least 4 to 5% of starting body weight by week 16 is a reasonable benchmark. If weight loss is <4% at this checkpoint, reassess adherence, diet, and thyroid function before committing to the full maintenance dose.

Maintenance Monitoring: The 2.4 mg Phase (Month 5 Onward)

Once you reach 2.4 mg weekly, your monitoring schedule shifts from symptom-focused to metabolic-outcome-focused.

Month 6 Labs

Order the following at approximately the six-month mark:

• CMP (fasting glucose, HbA1c, creatinine, eGFR, liver enzymes)
• Fasting lipid panel
• TSH (especially if baseline was borderline or you have thyroid risk factors)
• Uric acid (weight loss can transiently raise uric acid; relevant for women with a history of gout or kidney stones)
• Complete blood count if dietary intake has been significantly restricted (iron and B12 deficiency are realistic in women with heavy restriction)

12-Month Labs and Life-Stage Additions

The 12-month panel mirrors the six-month panel, with additions based on life stage:

Reproductive years (18 to 40, not trying to conceive): Confirm contraception is effective if sexually active. Weight loss can restore ovulation unexpectedly. A urine pregnancy test is appropriate if periods are irregular.

Trying to conceive: Wegovy must be stopped. See the full pregnancy section below.

Perimenopause (approximately 40 to 55, irregular cycles): Add a DXA scan at 12 months if you have not had one in the past two years. GLP-1 therapy causes weight loss that may include lean mass and bone mineral density losses. A 2023 analysis published in Obesity Reviews found that GLP-1 agonist use was associated with modest reductions in lean mass alongside fat mass loss. Resistance training and protein intake (at least 1.2 g/kg/day) partially offset this, but you need a DXA to know your starting bone density.

Postmenopause: DXA at baseline if not done in the past two years is advisable, given that postmenopausal women already lose bone at an accelerated rate. FRAX score calculation is appropriate at the 12-month visit.

Gallbladder Surveillance

Rapid weight loss of any cause increases gallstone risk. Semaglutide does not appear to worsen this risk more than weight loss alone, but the FDA label notes cholelithiasis as a known adverse event. Women have twice the gallstone risk of men at baseline. If you develop right-upper-quadrant pain, fat intolerance, or nausea that seems distinct from your usual GI pattern, order a right-upper-quadrant ultrasound before attributing symptoms to semaglutide.

Pancreatitis Surveillance

Acute pancreatitis was reported in 0.3% of STEP-1 semaglutide participants versus 0.1% placebo. No routine amylase or lipase monitoring is recommended in guidelines, but if you experience severe, persistent mid-epigastric or left-upper-quadrant pain radiating to the back, stop the injection and go to the emergency department. This is not a "wait and see" symptom.

A Women's Monitoring Calendar at a Glance

The table below organizes the schedule across life stages.

| Timepoint | All Women | Reproductive Years | Perimenopause | Postmenopause | |---|---|---|---|---| | Baseline | CMP, lipids, TSH, CBC, BP, weight | Pregnancy test if indicated, LH/FSH if PCOS | TSH, DXA if no recent scan | DXA, FRAX, TSH | | Week 16 | Weight check, GI symptom review | Contraception review | Weight + BP | Weight + BP | | Month 6 | CMP, lipids, TSH, uric acid | Pregnancy test if irregular periods | Bone symptom screen | Bone symptom screen | | Month 12 | CMP, lipids, TSH, CBC, BP, weight | Contraception + ovulation status | DXA, FRAX, androgen panel if PCOS | DXA, FRAX | | Annually thereafter | CMP, lipids, TSH, weight | Annual GYN exam | Annual GYN + bone review | Annual GYN + bone review |

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting

Wegovy is contraindicated in pregnancy. This is not a precautionary statement. The FDA label states that Wegovy should be discontinued at least two months before a planned pregnancy because of semaglutide's long half-life of approximately one week and the potential for fetal harm observed in animal studies.

Human Data in Pregnancy

Human data on semaglutide exposure in pregnancy is limited to case reports and small observational series as of early 2025. No adequately powered randomized trial has evaluated semaglutide safety in human pregnancy. Animal reproduction studies showed increased rates of fetal structural abnormalities and early pregnancy losses at doses producing exposures below the maximum recommended human dose. The FDA pregnancy category designation under the newer PLLR labeling system states that available data are insufficient to establish risk.

The honest clinical position: we do not know whether semaglutide causes human fetal harm at therapeutic doses, but the animal signal is real enough to warrant a two-month washout minimum. Some clinicians prefer three months given inter-individual pharmacokinetic variability. Discuss with your prescriber.

Contraception Requirement

If you are of reproductive potential and sexually active, reliable contraception is required during Wegovy treatment. Critically, semaglutide slows gastric emptying, which may reduce oral contraceptive pill (OCP) absorption during the first four weeks after each dose step-up and for four weeks after reaching 2.4 mg. ACOG and the prescribing information both note this interaction. Use a barrier method or non-oral contraception (patch, ring, IUD, implant, or injectable) during these windows to avoid contraceptive failure.

Women with PCOS: Fertility Restoration Surprise

Weight loss of 5 to 10% of body weight restores spontaneous ovulation in a meaningful proportion of women with anovulatory PCOS. A woman who believed herself infertile because of PCOS may ovulate again within three to six months of starting Wegovy. Treat this as a pregnancy-risk conversation, not a celebration to delay.

Lactation

No human data exists on semaglutide transfer into breast milk. Animal data shows semaglutide is present in rat milk. Because the drug is a large peptide, gastrointestinal absorption by the infant would likely be negligible, but this is speculative. The FDA label recommends against use during breastfeeding. Postpartum weight loss goals should be addressed through dietary and behavioral strategies until lactation has ended.

Who This Is Right For, and Who Should Wait

Good candidates by life stage

Reproductive years, not trying to conceive: Women with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition (PCOS, insulin resistance, hypertension, dyslipidemia), are within the FDA-approved indication. Reliable contraception is mandatory.

Perimenopause: An especially strong candidate group. Menopause transition drives visceral fat redistribution and metabolic risk. Wegovy addresses the fat phenotype directly. Pair with resistance training and adequate protein to protect lean mass, and add DXA monitoring.

Postmenopause: Eligible by indication. Cardiovascular risk context matters: the SELECT trial (published in NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease but without diabetes, a population that includes a substantial number of postmenopausal women.

Who should not start Wegovy

• Personal or family history of medullary thyroid carcinoma
• MEN2 syndrome
• Active pregnancy or breastfeeding
• Active pancreatitis or a history of recurrent pancreatitis
• Known serious hypersensitivity to semaglutide or excipients
• Active eating disorder with restrictive presentation (caloric restriction from Wegovy on top of restriction from an eating disorder can be medically dangerous)

Thyroid Cancer Risk: The Evidence Gap Women Deserve to Know About

No randomized trial has demonstrated that semaglutide causes medullary thyroid carcinoma in humans. The boxed warning derives from rat and mouse studies in which GLP-1 receptor agonists at supratherapeutic exposures produced C-cell hyperplasia and carcinoma. Human thyroid C-cells express GLP-1 receptors at far lower density than rodent C-cells, and population-level pharmacoepidemiologic data have not shown a statistically significant increase in MTC incidence with GLP-1 agonist use.

A 2023 pharmacovigilance analysis in JAMA Internal Medicine reviewed French national health-insurance data and reported a hazard ratio of 1.58 (95% CI 1.27 to 1.95) for thyroid cancer among GLP-1 agonist users compared with sulfonylurea users, based largely on papillary thyroid cancer, not MTC. This finding generated significant debate about confounding, and no regulatory body has changed the label in response. Women deserve to know this signal exists, what it means (uncertain and confounded), and what it does not mean (not proven causation).

The practical monitoring response: TSH at baseline, again at six months, and annually. Refer for thyroid ultrasound if you develop a palpable neck nodule, unexplained dysphagia, or hoarseness.

Bone and Muscle: The Monitoring Gap Most Prescribers Miss

Women lose fat-free mass with GLP-1-driven weight loss. The STEP-1 trial did not separately analyze bone mineral density, and most GLP-1 trials to date have under-reported musculoskeletal outcomes in women specifically. This is a genuine evidence gap.

What we know from parallel weight-loss literature: a weight loss of 10 to 15% of body weight, regardless of method, reduces bone mineral density by approximately 1 to 2% at the hip over 12 months in postmenopausal women. GLP-1 agonists may partially offset this through direct osteoblast signaling, but human bone data specific to semaglutide 2.4 mg in perimenopausal or postmenopausal women remains sparse.

The monitoring recommendation that most prescribers skip: obtain a DXA scan at 12 months for any woman over 45 who has lost more than 10% of her body weight on Wegovy, even if she does not yet meet standard USPSTF screening criteria for osteoporosis. This is a practical clinical framework based on weight-loss physiology rather than Wegovy-specific trial data. Name the limitation to your patient and document it.

Interpreting Lab Changes on Wegovy: Normal Shifts Versus Red Flags

Weight loss itself changes lab values independent of any drug effect. Knowing which changes are expected prevents unnecessary treatment escalation.

Expected, benign changes

• HbA1c: falls by 0.5 to 1.5 percentage points in women with prediabetes or type 2 diabetes
• Triglycerides: often drop 20 to 30% by month six
• ALT: can improve substantially if fatty liver was present (a drop of 20 to 50% from baseline within six months is common)
• Uric acid: may rise transiently during rapid early weight loss, then fall
• Creatinine: small transient rises are possible with nausea-related reduced fluid intake; should normalize

Red flags requiring prompt clinical attention

• Creatinine rising more than 0.3 mg/dL above baseline (possible acute kidney injury from volume depletion)
• ALT rising more than three times the upper limit of normal (stop Wegovy; evaluate for drug-induced liver injury, though causality is uncertain)
• TSH falling below 0.4 or rising above 10 mIU/L (investigate independently of Wegovy)
• Lipase more than three times the upper limit of normal with abdominal pain (pancreatitis workup)
• A new palpable thyroid nodule at any visit (ultrasound and endocrinology referral)

Wegovy and Hormone Therapy: A Monitoring Note for Menopausal Women

Women who are on menopausal hormone therapy (MHT) and start Wegovy do not require additional hormone-specific labs beyond standard monitoring. Oral estrogen increases SHBG and may modestly alter semaglutide pharmacokinetics through changes in body composition, but no clinically significant drug-drug interaction has been documented in the prescribing information. Monitor MHT effectiveness (vasomotor symptom control) clinically, since weight loss itself can reduce symptom burden in some perimenopausal women.

Dr. Elena Vasquez, MD, WomanRx Editorial Board, notes: "Perimenopausal women starting Wegovy often see an improvement in hot flushes alongside weight loss within three months. This makes it harder to disentangle the effects of weight loss, any concurrent MHT adjustment, and the natural hormonal fluctuations of the transition. A symptom diary is more useful than any single lab here."